Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging Bioidentical Hormones - U.S. Senate Special Committee on Aging
239 Written Testimony of Jane L. Murray, MD - Board Chair, Women in Balance Before the
240 Written Testimony of Steven F. Hotze, MD Before the
- Page 191 and 192: 188 Postmenopausal hormone therapy
- Page 193 and 194: group (P= 04001), and In this subgr
- Page 195 and 196: Treatmnent recommendations Based on
- Page 197 and 198: 21.Grodsteln F. Manson JE, Colditz
- Page 199 and 200: _ ORWIGNAL CONTIuBUTION 196 Postmen
- Page 201 and 202: showed no striking differences in H
- Page 203 and 204: (214 cases; P for trend=.72): howev
- Page 205 and 206: 202 HORMONE THERAPY USE AND RISK OF
- Page 207 and 208: mal studies, and laboratory studies
- Page 209 and 210: 206 HORMONE THERAPY USE AND RISK OF
- Page 211 and 212: 208 HORMONE THERAPY USE AND RISK OF
- Page 213 and 214: 210 ,lmcCII na: CLI I tr: tarty ver
- Page 215 and 216: 212 ,mucmai rimi &ronos farty bstro
- Page 217 and 218: 214 LntIucwu miau: rronos nary estr
- Page 219 and 220: XVI. PNharmacy Licensure Requiremen
- Page 221 and 222: XVI. Pharmacy Licensure Requirement
- Page 223 and 224: 220 Roster of Board of Pharmacy Ece
- Page 225 and 226: 050. 0l7404405400 Al-h. PeVbU 03283
- Page 227 and 228: Conclusions * Age is a powerful ris
- Page 229 and 230: Women's Health Initiative Trials of
- Page 231 and 232: Hormone Therapy after WHI * Change
- Page 233 and 234: Statement of the American Pharmacis
- Page 235 and 236: 232 APhA Statement to the S
- Page 237 and 238: 234 APhA Statement to the S
- Page 239 and 240: 236 APhA Statement to the S
- Page 241: 238 APhA Statement to the S
- Page 245 and 246: 242 STATEMENT OF DAVID G. ADAMS On
- Page 247 and 248: 244 Report on State Laws and Regula
- Page 249 and 250: 246 Only one state, Utah, requires
- Page 251: 248 5. Compounding Copies of FDA-Ap
240<br />
Written Testim<strong>on</strong>y of<br />
Steven F. Hotze, MD<br />
Before the <str<strong>on</strong>g>Senate</str<strong>on</strong>g> <str<strong>on</strong>g>Special</str<strong>on</strong>g> <strong>Aging</strong> <str<strong>on</strong>g>Committee</str<strong>on</strong>g> <strong>on</strong> April 19, 2007<br />
Federal interventi<strong>on</strong> into the practice of pharmacy, specifically compounding pharmacy,<br />
would prove detrimental to the health of many Americans. As a physician who has used<br />
compounded pharmacy medicati<strong>on</strong>s for years and who currently owns a compounding<br />
pharmacy, I have a unique perspective <strong>on</strong> ensuring compounded drugs are readily available<br />
to the patients who need them. It is comm<strong>on</strong> for physicians to determine that manufactured<br />
off the shelf prescripti<strong>on</strong> drugs are inadequate to meet the medical needs of an individual<br />
patient. Compounding pharmacy helps ensure the individualized treatment that patients<br />
both need and demand.<br />
Pharmacists who specialize in compounding prepare customized medicati<strong>on</strong>s in<br />
accordance with a doctor's prescripti<strong>on</strong>. These medicati<strong>on</strong>s, which are not produced by<br />
pharmaceutical companies, are prepared using FDA approved bulk products and are<br />
provided to meet specific patient needs. Through clinical experience, a physician may<br />
decide to use alternative delivery systems (e.g. suppositories, creams, gels, liquids or<br />
capsules) for a specific medicati<strong>on</strong>. Often compounded medicati<strong>on</strong>s are not commercially<br />
available in the strength requested by the physician. In other cases, a patient may be<br />
allergic to the dyes, additives or excipients found in drugs produced by pharmaceutical<br />
manufacturers. In this situati<strong>on</strong>, the soluti<strong>on</strong> is prepared without the allergy causing<br />
ingredients. Compounding pharmacy allows physicians to provide patients with alternative<br />
therapies otherwise not commercially available.<br />
The Food, Drug, and Cosmetic Act (FDCA) of 1938 established the authority of the Food<br />
and Drug Administrati<strong>on</strong> (FDA) over the pharmaceutical manufacturing of drugs.<br />
Pharmacies were specifically exempted from FDA regulati<strong>on</strong> and their governance was<br />
delegated to the State boards of pharmacy. At that time, all pharmacies practiced the<br />
compounding of medicati<strong>on</strong>s. Pharmacies, including compounding pharmacies, should<br />
remain under the regulati<strong>on</strong> of the States.<br />
Most pharmacists, like others in business, realize that their self-interest is best served by<br />
operating their enterprises with the interests of their customers in mind. To do otherwise<br />
would result in a loss of business. State laws address the issue of fraudulent and dangerous<br />
business practices. State boards of pharmacy establish guidelines for safely c<strong>on</strong>ducting<br />
pharmacy practices and procedures.<br />
The recent results of the Women's Health Initiative study dem<strong>on</strong>strate the danger of drug<br />
company, FDA-approved, counterfeit horm<strong>on</strong>es. Compounding pharmacies are able to<br />
offer physicians a natural, safe and effective treatment for women in midlife. That<br />
treatment is biologically identical horm<strong>on</strong>e therapy that provides women with the same<br />
horm<strong>on</strong>es that their bodies used to produce or currently produce in less than adequate<br />
amounts. With the baby boomer populati<strong>on</strong> aging, there are milli<strong>on</strong>s up<strong>on</strong> milli<strong>on</strong>s of